Rogaine first year sales trending at over $100 mil. based on IRI data through November.
This article was originally published in The Tan Sheet
ROGAINE FIRST YEAR OTC SALES TRENDING AT OVER $100 MIL., according to data from Information Resources, Inc. Launched in April, the Rx-to-OTC switch product showed sales through November of $96.8 mil. in food, drug and mass merchandiser outlets, constituting an 86.8% dollar share of the hair regrowth market. Pharmacia & Upjohn has predicted that five-year OTC Rogaine sales will total $650 mil. ("The Tan Sheet" May 13, 1996, In Brief)
You may also be interested in...
Companies marketing dexamethasone in Europe have been told they can use a CHMP endorsement to request the addition of COVID-19 to their product license.
Redirection of healthcare resources to tackle COVID-19 is posing huge challenges for TB care and researchers in the area. Companies like J&J have stepped in to support, among other aspects, innovative community-based solutions to ensure continuity of care for drug resistant-TB patients amid the pandemic.
After a high-profile launch early this year, first-mover Perrigo has recalled its albuterol sulfate aerosol in the US following complaints of inhalers failing to dispense due to “clogging.” The firm has revealed the expected financial impact of the move as well as commenting on how long it expects the product to be off the market, during which albuterol rivals Cipla and Lupin could benefit.